NanoDx, Inc. is a privately-held, U.S. based, medical device company developing rapid point-of-care and in-vitro diagnostic products on its proprietary nanowire biosensor platform. The NanoDx™ System provides for direct measurement of blood and saliva analytes normally in less than 2 minutes from either a drop of whole blood or a small sample of saliva. In partnership with IBM and SkyWater Technologies, a low-cost, high-volume, licensed CMOS process has been integrated into NanoDx’s highly-advanced proprietary platform. The System consists of a single-use, disposable test cartridge and an analyzer. The company is focused on two near-term indications: traumatic brain injury (TBI) and Covid-19. The NanoDx™ System offers compelling competitive advantages based on its ultra-sensitivity and accuracy, speed, value, and ease-of-use. Additional potential diseases and conditions include stroke, sepsis, influenza and inflammatory diseases.
FDA has not yet reviewed this product and it has not been cleared. Currently for research use only.
Company’s Keywords:
biotechnology, life sciences, traumatic brain injury
<23
<1400000
<2010